COMP <GO>
NUVB vs RARE // ENTERPRISE SCALE & MARKET CAP
Nuvation Bio Inc. (Class A) (NYSE) VS. Ultragenyx Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: NUVB 4
— RARE 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: NUVB
LAST: $4.77 (+3.92%) • MKT CAP: $1.67B
market-cap
$1.67B
LAST: $16.78 (-2.44%) • MKT CAP: $1.65B
market-cap
$1.65B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUVB VS. RARE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUVB | RARE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.35% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 20.20% | +159.80 | NUVB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.76 | 0.20 | +0.56 | NUVB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | NUVB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.6 | 54.9 | -12.30 | RARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.67B | $1.65B | $20.5M | NUVB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUVB REV | RARE REV | NUVB GROSS % | RARE GROSS % | NUVB FCF | RARE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.9M | $673.0M | — | — | -$173.4M | -$472.0M |
| FY 2024 | $7.9M | $560.0M | 10.1% | — | -$130.4M | -$421.0M |
| FY 2023 | $0 | $434.0M | — | — | -$68.0M | -$475.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUVB // BETA —
RARE // BETA —